Arenarine C

Arenarine C

SCHEMBL645800

COc1ccc2c(c1)[nH]c1c(C(C)=O)nccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 14/20 1.00
ACHE P22303 3/20 1.00
BCHE P06276 3/20 1.00
MAOA P21397 3/20 0.65
GSK3B P49841 2/20 0.65
CLK1 P49759 2/20 0.65
CDK5 Q00535 2/20 0.65
CDK5R1 Q15078 2/20 0.65
KDM4E B2RXH2 1/20 0.65
DYRK3 O43781 1/20 0.65
CCNT1 O60563 1/20 0.65
CCNB2 O95067 1/20 0.65
ALDH1A1 P00352 1/20 0.65
CYP1A2 P05177 1/20 0.65
CDK1 P06493 1/20 0.65
CYP3A4 P08684 1/20 0.65
ADRA2A P08913 1/20 0.65
CYP2D6 P10635 1/20 0.65
CCNB1 P14635 1/20 0.65
HPGD P15428 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arenarine C SCHEMBL30199121 1.00 DYRK1A (1.00) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL25832010 0.90 DYRK1A (0.81) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL30601059 0.90 DYRK1A (0.81) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL25832011 0.88 DYRK1A (0.79) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL30199348 0.88 DYRK1A (0.79) DYRK1AACHEBCHEMAOAGSK3B
Harmic Acid Methyl Ester SCHEMBL25294090 0.88 DYRK1A (0.79) DYRK1AACHEBCHEMAOAGSK3B
Trigonostemine B SCHEMBL30492900 0.82 DYRK1A (0.69) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL2768479 0.81 DYRK1A (0.68) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL2768305 0.81 DYRK1A (0.68) DYRK1AACHEBCHEMAOAGSK3B
SCHEMBL16123485 0.79 DYRK1A (0.74) DYRK1AACHEBCHEMAOAGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2926119-B1 METHOD OF MARKING OF MATERIAL, MARKED MATERIAL AND METHOD FOR AUTHENTICATING A MATERIAL SICPA HOLDING SA (CH) 2023-02-22 EP claimed
EP-2926119-A1 MARKING OF MATERIAL, MARKED MATERIAL AND PROCESS OF AUTHENTICATION OR DILUTION DETERMINATION Sicpa Holding SA (CH) 2015-10-07 EP claimed
WO-2014083145-A1 MARKING OF MATERIAL, MARKED MATERIAL AND PROCESS OF AUTHENTICATION OR DILUTION DETERMINATION SICPA HOLDING SA (CH) 2014-06-05 WO claimed
US-20140154813-A1 MARKING OF MATERIAL, MARKED MATERIAL AND PROCESS OF AUTHENTICATION OR DILUTION DETERMINATION SICPA HOLDING SA (CH) 2014-06-05 US claimed
US-20250171749-A1 GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS Empyrean Neuroscience, Inc. 2025-05-29 US disclosed
EP-4457336-A2 GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS Empyrean Neuroscience, Inc. (US) 2024-11-06 EP disclosed
US-12104179-B2 Genetically modified organisms for producing psychotropic alkaloids Empyrean Neuroscience, Inc. (US) 2024-10-01 US disclosed
US-20240132494-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2024-04-25 US disclosed
US-20240101976-A1 GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS Empyrean Neuroscience, Inc. 2024-03-28 US disclosed
US-11866427-B2 Kinase inhibitor compounds and compositions and methods of use ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-01-09 US disclosed
WO-2023130078-A2 GENETICALLY MODIFIED MYCELIUM FOR PRODUCING PSYCHOTROPIC ALKALOIDS Empyrean Neuroscience, Inc. (US) 2023-07-06 WO disclosed
WO-2023130076-A2 TARGETS AND PATHWAYS FOR THE PRODUCTION OF ALKALOIDAL COMPOUNDS Empyrean Neuroscience, Inc. (US) 2023-07-06 WO disclosed
US-8119660-B2 Small-molecule inhibitors of the androgen receptor THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-21 US disclosed
US-20110224253-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-09-15 US disclosed
EP-2276345-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR The Regents of the University of California (US) 2011-01-26 EP disclosed
US-20100168128-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-01 US disclosed
US-7696227-B2 Small-molecule inhibitors of the androgen receptor REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-13 US disclosed
WO-2009132307-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-10-29 WO disclosed
US-20080293766-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-11-27 US disclosed
WO-2008128100-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132494-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE CSNK1A1, DYRK1A, CSNK1G3 DYRK1A 2/4885ACHE 745/4885BCHE 1197/4885
US-20100168128-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR AR, GNRHR, FSHR DYRK1A 3694/4885ACHE 4255/4885BCHE 3634/4885
US-11866427-B2 Kinase inhibitor compounds and compositions and methods of use CSNK1A1, CSNK1E, CSNK1G3 DYRK1A 7/4885ACHE 831/4885BCHE 1300/4885
US-20250171749-A1 GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS PNMT, INMT, AANAT DYRK1A 569/4885ACHE 81/4885BCHE 31/4885
US-20240101976-A1 GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS PNMT, INMT, AANAT DYRK1A 569/4885ACHE 81/4885BCHE 31/4885
US-20080293766-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR AR, GNRHR, FSHR DYRK1A 3694/4885ACHE 4255/4885BCHE 3634/4885
US-12104179-B2 Genetically modified organisms for producing psychotropic alkaloids PNMT, INMT, AANAT DYRK1A 569/4885ACHE 81/4885BCHE 31/4885
US-20110224253-A1 SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR AR, NR5A1, CYP17A1 DYRK1A 2516/4885ACHE 4571/4885BCHE 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.